Literature DB >> 33737039

Functional vision disorders in adults: a paradigm and nomenclature shift for ophthalmology.

Subahari Raviskanthan1, Sydney Wendt2, Peter M Ugoh2, Peter W Mortensen1, Heather E Moss3, Andrew G Lee4.   

Abstract

Vision loss with clinical findings that are incompatible with the symptoms and recognized neurological or ophthalmic conditions is a common presentation of patients to neurologists, ophthalmologists, and neuro-ophthalmologists. The accepted terminology to describe such patients has evolved over time, including functional visual disorder (FVD), non-organic vision loss, non-physiologic vision loss, functional vision loss, psychogenic, psychosomatic, and medically unexplained visual loss. Likewise, attitudes and recommended management options have changed over the years in the fields of psychiatry and neurology. FVD is a diagnosis of inclusion, and it is critical that the diagnosis be made and delivered efficiently and effectively to reduce patient and physician duress. We review the current Diagnostic and Statistical Manual (DSM V) terminology and the prior literature on FVD and describe how the approaches to diagnosis and management have changed. We provide recommendations on the appropriate techniques and diagnostic approach for patients with FVD. We also propose a protocol for consistent and standardized discussion with the patient of the diagnosis of FVD. We believe that the adoption of FVD as both a paradigm and nomenclature shift in ophthalmology will improve patient care.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Functional vision disorder; SPIKES; functional neurologic disorder; functional visual loss; medically unexplained vision loss; non-organic vision loss; psychogenic vision loss

Mesh:

Year:  2021        PMID: 33737039      PMCID: PMC9159904          DOI: 10.1016/j.survophthal.2021.03.002

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.197


  50 in total

Review 1.  Non-organic visual loss.

Authors:  S Beatty
Journal:  Postgrad Med J       Date:  1999-04       Impact factor: 2.401

2.  Family carers' experiences of receiving the news of a diagnosis of Motor Neurone Disease: A national survey.

Authors:  Samar M Aoun; Lauren J Breen; David Oliver; Robert D Henderson; Robert Edis; Margaret O'Connor; Denise Howting; Rodney Harris; Carol Birks
Journal:  J Neurol Sci       Date:  2016-11-20       Impact factor: 3.181

Review 3.  Conversion disorder: A systematic review of current terminology.

Authors:  Juen Mei Ding; Richard Antony Alexander Kanaan
Journal:  Gen Hosp Psychiatry       Date:  2016-12-24       Impact factor: 3.238

4.  A review of practical tests for ocular malingering and hysteria.

Authors:  B W Miller
Journal:  Surv Ophthalmol       Date:  1973 Jan-Feb       Impact factor: 6.048

Review 5.  Functional disease in neuro-ophthalmology.

Authors:  C H Smith; R W Beck; R P Mills
Journal:  Neurol Clin       Date:  1983-11       Impact factor: 3.806

6.  SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer.

Authors:  W F Baile; R Buckman; R Lenzi; G Glober; E A Beale; A P Kudelka
Journal:  Oncologist       Date:  2000

Review 7.  Functional and simulated visual loss.

Authors:  M Dattilo; V Biousse; B B Bruce; N J Newman
Journal:  Handb Clin Neurol       Date:  2016

Review 8.  Functional vision loss.

Authors:  John Pula
Journal:  Curr Opin Ophthalmol       Date:  2012-11       Impact factor: 3.761

9.  Functional visual loss. Follow-up of 42 cases.

Authors:  R G Kathol; T A Cox; J J Corbett; H S Thompson
Journal:  Arch Ophthalmol       Date:  1983-05

10.  Perimetric findings in functional disorders using automated techniques.

Authors:  T J Smith; R S Baker
Journal:  Ophthalmology       Date:  1987-12       Impact factor: 12.079

View more
  1 in total

Review 1.  Management of Functional Vision Disorders.

Authors:  Ragini Phansalkar; A Juliana Lockman; Surbhi Bansal; Heather E Moss
Journal:  Curr Neurol Neurosci Rep       Date:  2022-03-23       Impact factor: 6.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.